Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
14.7 USD | -2.58% |
|
+3.57% | -61.37% |
04/06 | Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing | MT |
31/05 | Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index | CI |
Sales 2022 | 2.19M 183M | Sales 2023 | 1.8M 150M | Capitalization | 1.8B 150B |
---|---|---|---|---|---|
Net income 2022 | -145M -12.11B | Net income 2023 | -241M -20.13B | EV / Sales 2022 | 459 x |
Net cash position 2022 | 66.76M 5.58B | Net cash position 2023 | 67.78M 5.66B | EV / Sales 2023 | 961 x |
P/E ratio 2022 |
-6.8
x | P/E ratio 2023 |
-7.42
x | Employees | 169 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 21.13% |
1 day | -2.72% | ||
Current month | -56.96% | ||
1 month | -57.26% | ||
3 months | -58.14% | ||
6 months | -56.31% | ||
Current year | -61.37% |
![Extreme 14.66](/images/extremecours_fleche.png)
![Extreme 14.66](/images/extremecours_fleche.png)
![Extreme 14.305](/images/extremecours_fleche.png)
![Extreme 7.67](/images/extremecours_fleche.png)
![Extreme 7.67](/images/extremecours_fleche.png)
![Extreme 7.67](/images/extremecours_fleche.png)
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.20% | 12 M€ | -.--% | - | |
0.09% | 2 M€ | -.--% | ||
0.07% | 0 M€ | 0.00% | - | |
0.05% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
27/24/27 | 14.7 | -2.58% | 77 128 |
25/24/25 | 15.09 | -2.46% | 160,778 |
24/24/24 | 15.47 | +2.18% | 144,735 |
21/24/21 | 15.14 | +4.49% | 836,123 |
20/24/20 | 14.49 | -0.55% | 210,201 |
Delayed Quote Nasdaq, June 27, 2024 at 12:33 am IST
More quotes1st Jan change | Capi. | |
---|---|---|
-61.37% | 1.79B | |
+16.56% | 122B | |
+21.52% | 116B | |
+22.18% | 27.03B | |
-21.48% | 20.36B | |
-16.89% | 16.43B | |
-18.17% | 15.91B | |
-44.74% | 15.6B | |
+61.80% | 14.94B | |
+3.25% | 13.59B |
- Stock Market
- Equities
- INBX Stock